Cat. No：GM-C27728
Product：ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line
Cat. No：GM-C27728
Product：ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1 % FBS+1% P.S
ADCP, or Antibody-Dependent Cellular Phagocytosis, refers to the process where immune cells expressing Fc receptors engulf target cells by recognizing the Fc segment of antibodies that bind specifically to the target cell. Today, the mechanism of ADCP is utilized to detect and assess the efficacy of antibodies. When the Fab segment of an antibody binds to a target antigen on the cell surface, and the Fc segment simultaneously binds to the FcγRIIa receptor on the effector cell surface (primarily macrophages), crosslinking occurs, activating the ADCP pathway leading to the engulfment of the target cell. In classic ADCP bioactivity assays, a donor's macrophage subset is used as the effector cell. These cells exhibit significant response variability, making them difficult to prepare and prone to high background readings.
Genomeditech ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line utilizes engineered Jurkat cells as effector cells. Through clever vector design and a third-generation lentiviral reporter gene system, stable expression of human FcγRIIa receptor (131H) and firefly luciferase driven by a transcription factor is achieved. The biological activity of antibodies in the ADCP mechanism is quantified through the luminescence activated by the NFAT pathway, while the luciferase activity in effector cells is quantified through bioluminescent readings. This method provides high signal values and low background values. Customized ADCP cell lines and ADCP activity detection services are also available.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa Jurkat Effector Cell Line |
| ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line | |
Cat. No：GM-C27728
Product：ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1 % FBS+1% P.S
ADCP, or Antibody-Dependent Cellular Phagocytosis, refers to the process where immune cells expressing Fc receptors engulf target cells by recognizing the Fc segment of antibodies that bind specifically to the target cell. Today, the mechanism of ADCP is utilized to detect and assess the efficacy of antibodies. When the Fab segment of an antibody binds to a target antigen on the cell surface, and the Fc segment simultaneously binds to the FcγRIIa receptor on the effector cell surface (primarily macrophages), crosslinking occurs, activating the ADCP pathway leading to the engulfment of the target cell. In classic ADCP bioactivity assays, a donor's macrophage subset is used as the effector cell. These cells exhibit significant response variability, making them difficult to prepare and prone to high background readings.
Genomeditech ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line utilizes engineered Jurkat cells as effector cells. Through clever vector design and a third-generation lentiviral reporter gene system, stable expression of human FcγRIIa receptor (131H) and firefly luciferase driven by a transcription factor is achieved. The biological activity of antibodies in the ADCP mechanism is quantified through the luminescence activated by the NFAT pathway, while the luciferase activity in effector cells is quantified through bioluminescent readings. This method provides high signal values and low background values. Customized ADCP cell lines and ADCP activity detection services are also available.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa Jurkat Effector Cell Line |
| ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line | |
